Last reviewed · How we verify
NCT05902494
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
trial in Urothelial Carcinoma in 389 participants. Completed in 18 June 2025.
18 June 2025
Quick facts
| Lead sponsor | Seagen, a wholly owned subsidiary of Pfizer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 389 |
| Start date | 29 June 2023 |
| Primary completion | 18 June 2025 |
| Estimated completion | 18 June 2025 |
| Sites | 23 locations across Austria, France, United States, Germany |
Conditions studied
- Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Sponsor
Seagen, a wholly owned subsidiary of Pfizer — full company profile →
Who can join
18 and older, any sex, with Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05902494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting
Other Seagen, a wholly owned subsidiary of Pfizer trials
Trials by the same sponsor.
- NCT06549816 — A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors · Phase 1 · completed
- NCT06466187 — A Study of SGN-MesoC2 in Advanced Solid Tumors · Phase 1 · active not recruiting
- NCT06254495 — A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers · Phase 1 · active not recruiting
- NCT06157892 — A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors · Phase 2 · recruiting
- NCT06120504 — A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05902494 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05902494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing